Logo

Luminex Q3 Revenues Climb 28.6 Percent, Losses Decline

Oct 27, 2005

NEW YORK, Oct. 27 (GenomeWeb News) - Luminex yesterday reported increased revenues and a narrowing loss for the third quarter of 2005 as a result of increased R&D investment.

 

Revenues for third quarter ended Sept. 30 totaled $10.8 million, a 28.7 percent increase over last year's revenues of $8.4 million during the same quarter. Of total revenues, $4.6 million came from sales of Luminex instruments, $3.4 million from consumables, $1.4 million from royalties, and $1.3 million from other sources such as training, extended service contract sales, and other special project revenue.

 

Research and development costs climbed to $1.5 million, up from $949,000 during the year-ago quarter.

 

Luminex's net loss declined 43 percent to $657,000, or $.02 per share, from $1.2 million, or $.04 per share, for last year's third quarter.

 

As of Sept. 30, Luminex had $21.5 million in cash and cash equivalents, and $10.9 million in short-term investments.

Breaking News
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.